Novavax, a biotechnology company specializing in vaccine development, has reported a significant event concerning its stock. Dr. Ruxandra Draghia-Akli, a director of Novavax, filed an Initial Statement of Beneficial Ownership of Securities with the United States Securities and Exchange Commission (SEC) on November 11, 2024. The filing, known as Form 3, is a requirement for directors, officers, or significant shareholders of public companies to declare their ownership of company stock. The form was signed by Mark J. Casey, Attorney-in-Fact, on November 13, 2024. According to the document, Dr. Draghia-Akli does not beneficially own any securities in the company at the time of the filing. This filing is in compliance with Section 16(a) of the Securities Exchange Act of 1934 and is a routine disclosure for individuals in Dr. Draghia-Akli's position.

Novavax, a biotechnology company specializing in vaccine development, has reported a significant event concerning its stock. Dr. Ruxandra Draghia-Akli, a director of Novavax, filed an Initial Statement of Beneficial Ownership of Securities with the United States Securities and Exchange Commission (SEC) on November 11, 2024. The filing, known as Form 3, is a requirement for directors, officers, or significant shareholders of public companies to declare their ownership of company stock. The form was signed by Mark J. Casey, Attorney-in-Fact, on November 13, 2024. According to the document, Dr. Draghia-Akli does not beneficially own any securities in the company at the time of the filing. This filing is in compliance with Section 16(a) of the Securities Exchange Act of 1934 and is a routine disclosure for individuals in Dr. Draghia-Akli's position.